Non-albumin proteinuria as a candidate biomarker of treatment response to finerenone in diabetic kidney disease: a real-world cohort study.
文献摘要
Introduction Finerenone reduces albuminuria and improves kidney outcomes in patients with diabetic kidney disease (DKD); however, its association with changes in non-albumin proteinuria (NAP), enriched for tubular injury-related proteins, remains unclear. We evaluated whether finerenone treatment was associated with a reduction in NAP and identified clinical phenotypes associated with a greater NAP response. Methods We retrospectively analyzed 477 patients treated with finerenone who had baseline urine albumin-to-creatinine ratio (uACR) and urine protein-to-creatinine ratio (uPCR) measurements from the same urine specimen. Urine non-albumin protein-to-creatinine ratio (uNAPCR) was calculated as uPCR minus uACR. Patients were stratified by baseline proteinuria severity (uPCR Results At baseline, median uPCR, uACR, and uNAPCR were 1140 [580, 2290], 716 [328, 1593], and 410 [223, 700] mg/gCr, respectively. At 6 months, uACR and uNAPCR declined by 30.3% and 17.5%, respectively. Subgroup analyses revealed differential associations: patients with higher baseline proteinuria (uPCR ≥ 500 mg/gCr) showed an 18.8% decline in uNAPCR, whereas those with uPCR Discussion Finerenone treatment was associated with a reduction in NAP, particularly among patients with higher baseline proteinuria, suggesting a possible effect on tubulointerstitial injury-related processes beyond albuminuria reduction. Prospective multicenter studies are needed to validate uNAPCR as a treatment-response biomarker against clinical endpoints.